Clinical trial
A Single Arm, Open-label, Multicenter, Phase II Clinical Study to Evaluate the Safety and Efficacy of 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
NCT07314723 is registered in ClinicalTrials.gov with Mabwell (Shanghai) Bioscience Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Arm, Open-label, Multicenter, Phase II Clinical Study to Evaluate the Safety and Efficacy of 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
- Lead sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- August 1, 2025
- Completion date
- December 31, 2028
- Enrollment
- 90 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
urothelial carcinoma